

Date: 31-10-2020

To
Mr. BhushanMokashi
Manager
Bombay Stock Exchange Limited,
PhirozeJeeJeebhoy Towers,
Dalal Street, MUMBAI – 400 001.

Sir,

Sub: Outcome of the Board Meeting – Reg.D
Ref: Our Company code no: 532041.

The following is the Outcome of the Board Meeting of the Company held on 31st October, 2020 at 03.00 P.M. at the registered office of the Company:

- 1 The Board has approved the un-audited financial results of the company for the quarter ended on 30th September, 2020.

We are herewith enclosing un-audited financial results of the company & Limited Review Report certified by the auditor for the quarter ended 30.09.2020, as per Clause 33 (3) of SEBI (LODR) Regulations, 2015.

This is for your information and record.

Thanking you

Yours faithfully,
For Hindustan Bio Sciences Limited



J Varun Varma
Director

STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER, 2020

(Rs. In lakhs)

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2019 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
1	Income from Operations						
	(a) Revenue from operations	32.71	55.48	13.95	88.19	71.47	194.33
	(b) Other Income	-	-	-	-	-	-
	Total Revenue (1)	32.71	55.48	13.95	88.19	71.47	194.33
2	Expenses						
	(a) cost of material consumed	-	-	-	-	-	-
	(b) Purchases of Stock -in-trade	13.55	20.48	6.43	34.03	56.00	152.69
	(c) Changes in Inventories of finished goods, Stock - in-Trade and Work-in-Progress	7.09	16.82	9.39	23.91	(9.68)	(22.63)
	(d) Employee Benefit Expenses	6.07	6.17	6.30	12.24	12.64	25.73
	(e) Finance Costs	0.07	0.23	0.30	0.30	0.47	0.82
	(f) Selling Expenses	0.24	0.38	0.15	0.62	0.24	0.55
	(g) Depreciation and amortisation Expenses	0.17	0.16	0.32	0.33	0.60	1.14
	(h) Other Expenses	2.57	6.20	5.29	8.77	11.53	24.38
	Total Expenses(2)	29.76	50.44	28.18	80.20	71.80	182.68
3	Profit/(Loss) before Exceptional & Extraordinary Items and tax (1 -2)	2.95	5.04	(14.23)	7.99	(0.33)	11.65
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) before tax(3 -4)	2.95	5.04	(14.23)	7.99	(0.33)	11.65
6	Tax Expenses						
	(a) Current Tax	-	-	-	-	-	1.82
	(b) Deferred Tax	-	-	-	-	-	1.74
7	Profit /(Loss) for the period from continuing operations(5-6)	2.95	5.04	(14.23)	7.99	(0.33)	8.09
8	Profit /(Loss) from discontinued operations	-	-	-	-	-	-
9	Tax Expense of discontinued operations	-	-	-	-	-	-
10	Profit /Loss from Discontinued operations after tax(8-9)	-	-	-	-	-	-
11	Profit/(Loss) for the period(7+10)	2.95	5.04	(14.23)	7.99	(0.33)	8.09
12	Other Comprehensive Income						
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will not be re- classified to profit or loss	-	-	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	2.95	5.04	(14.23)	7.99	(0.33)	8.09
14	Paid up Equity Capital(Face value of Rs. 10/- each)	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						(800.64)
16	Earnings per equity share for continuing operations						
	(A) Basic	0.03	0.05	(0.14)	0.08	(0.00)	0.08
	(B) Diluted	0.03	0.05	(0.14)	0.08	(0.00)	0.08
17	Earnings per equity share for discontinuing operations						
	(A) Basic	-	-	-	-	-	-
	(B) Diluted	-	-	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations						
	(A) Basic	0.03	0.05	(0.14)	0.08	(0.00)	0.08
	(B) Diluted	0.03	0.05	(0.14)	0.08	(0.00)	0.08

(Signature)



HINDUSTAN BIO SCIENCES LIMITED
Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
Phone No. 23555161, Fax 40205171

STATEMENT OF ASSETS AND LIABILITIES

(Rs. In Lakhs)

	PARTICULARS	(Rs. In Lakhs)	
		As at 30.09.2020	As at 31.03.2020
	ASSETS		
1	Non Current Assets		
	(a) Fixed Assets		
	Tangible Assets	4.45	4.77
	(b) Deferred Tax Asset	1.03	1.03
	(c) Long Term Loans & Advances	319.20	353.75
	Total Non Current Assets	324.68	359.55
2	Current Assets		
	(a) Stock in Trade	10.09	34.01
	(b) Trade Receivables	112.24	136.32
	(c) Cash and Cash Equivalents	1.83	19.67
	(d) Short Term Loans and Advances	6.80	6.24
	Total Current Assets	130.96	196.24
	TOTAL ASSETS	455.64	555.79
	EQUITY AND LIABILITIES		
1	Share Holders Funds		
	(a) Share Capital	1025.08	1025.08
	(b) Reserves and Surplus	(792.64)	(800.64)
	Total of Share Holders Funds	232.44	224.44
2	Non Current Liabilities		
	(a) Long Term Borrowings	67.37	166.61
	Total Non Current Liabilities	67.37	166.61
3	Current Liabilities		
	(a) Short Term Borrowings	98.74	93.10
	(b) Trade Payables		
	i. Total Outstanding dues of Micro Enterprises & Small Enterprises	0.00	0.15
	ii Total Outstanding dues of Creditors other than Micro Enterprises and small enterprises	52.18	65.97
	Other Current Liabilities	0.00	0
	Short Term Provisions	4.91	5.52
	Sub Total -Current Liabilities	155.83	164.74
	TOTAL EQUITY AND LAIBILITIES	455.64	555.79

Notes:

- 1 The Un Audited Financial Results were taken on record by the Board of Directors in their meeting held on 31.10.2020
- 2 Previous Year figures have been regrouped wherever necessary.

Place: Hyderabad
Date: 31.10.2020

for Hindustan Bio Sciences Limited

J.Varun Varma
Director



HINDUSTAN BIO SCIENCES LIMITED
Un audited Standalone Cash Flow Statement

Rs. In Lakhs

Particulars	30th September 2020	30th September 2019
	Rs.	Rs.
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit/(Loss) Before Tax	7.99	(0.33)
Adjustments for:		
Depreciation	0.33	0.60
Operating Profit before Working Capital Changes	8.32	0.27
Movements in Working Capital		
Increase/(Decrease) in Trade Payables	(13.94)	(5.85)
Decrease/(Increase) in Short Term Provisions	(0.61)	(0.85)
Increase/(Decrease) in Other Current Liabilities	5.64	12.50
Increase/(Decrease) in Trade Receivables	24.08	71.60
Increase/(Decrease) in Inventories	23.92	(9.68)
Decrease/(Increase) in Long Term Loans & Advances	34.55	0.11
Decrease/(Increase) in Short Term Loans & Advances	(0.56)	(1.29)
Cash generated from operations	81.40	66.81
Less: Income Tax paid	-	-
Net Cash flow from Operating activities	81.40	66.81
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	-	(0.97)
Net Cash used in Investing activities	-	(0.97)
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long Term Borrowings	(99.24)	(78.60)
Net Cash used in financing activities	(99.24)	(78.60)
Net increase in cash & Cash Equivalents	(17.84)	(12.76)
Cash and Cash equivalents at the beginning of the year	19.67	18.34
Cash and Cash equivalents at the end of the year	1.83	5.58

FOR HINDUSTAN BIO SCIENCES LIMITED

J. Varun Varma
Director



Place: Hyderabad
Date : 31.10.2020



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
M/S HINDUSTAN BIO SCIENCES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **M/s HINDUSTAN BIO SCIENCES LIMITED** (the "Company"), for the quarter and half year ended September 30, 2020, being prepared by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

The Preparation of this statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("IND AS 34"), prescribed under section 133 of the companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India is the Responsibility of the company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: October 31st, 2020



For C.RAMACHANDRAM & CO.,
Chartered Accountants
FR No. 002864S

N. Madhusudan Reddy
N.MADHUSUDAN REDDY
Partner

Membership No. 241624
UDIN: 20241624AAAJS2969